Bankrupt Traversa Settles IP Dispute as Alnylam, Isis Claim Delays in Tekmira Suit | GenomeWeb

The intellectual property ownership dispute between a former Traversa Therapeutics executive and the bankrupt company has been settled, with the executive buying the US patent application at issue, Gene Silencing News has learned.

With the IP in hand, Traversa's former director of chemistry Scott Petersen is continuing his efforts to find a pharmaceutical company interested in acquiring the application, No. 20110294869, and hiring him to continue development of the RNAi drug-delivery technology it covers, he said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.